All In MedTech

Device Trial Radar · NCT03729453

Intra-operative Pancreatoscopy in Patients With IPMN

Intra-operative Pancreatoscopy in Patients With Intraductal Papillary Mucinous Neoplasm (IPMN)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Actual

Start

Mar 20, 2019

Primary completion

Aug 11, 2022

Study completion May 2027

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Nov 2, 2018

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous (skip) lesions in the remnant pancreas; to generate a hypothesis for a subsequent randomized control trial.

Conditions

  • Intraductal Papillary Mucinous Neoplasm

Interventions

  • SpyGlassDevice

    Visualization of main pancreatic duct with SpyGlass catheter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of detection of discontinuous (skip) lesions along the main pancreatic ductTime frame: During index procedure

Locations

8 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Colorado Hospital

    Denver, Colorado

  • Indiana University Health

    Indianapolis, Indiana

  • Johns Hopkins Hospital University

    Baltimore, Maryland

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.